Faruqi & Faruqi Investigating Nutex Health Securities Lawsuit
ByAinvest
Wednesday, Aug 27, 2025 10:51 am ET1min read
NUTX--
The lawsuit alleges that Nutex Health Inc. violated federal securities laws by making false and/or misleading statements and/or failing to disclose key information. Specifically, the complaint alleges that Nutex engaged in a coordinated scheme with HaloMD to defraud insurance companies, resulting in unsustainable revenues. Additionally, the company overstated its ability to remediate material weaknesses in its internal controls over financial reporting and improperly calculated stock-based compensation obligations [1][2][3].
Investors who purchased or acquired Nutex securities during the specified period are urged to contact Faruqi & Faruqi partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The firm has a proven track record of recovering hundreds of millions of dollars for investors since its founding in 1995.
References:
[1] https://www.prnewswire.com/news-releases/nutex-health-nutx-securities-suit-alleges-fraud-and-financial-misstatements---hagens-berman-302538433.html
[2] https://www.morningstar.com/news/business-wire/20250825464928/nutx-investors-have-opportunity-to-lead-nutex-health-inc-securities-fraud-lawsuit-with-the-schall-law-firm
[3] https://www.marketscreener.com/news/investor-deadline-approaching-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-nu-ce7c50dede89f726
Faruqi & Faruqi LLP is investigating potential claims against Nutex Health Inc. regarding securities issued between August 8, 2024, and August 15, 2025. Investors who suffered losses are encouraged to contact James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek the role of lead plaintiff is October 21, 2025.
Investors who suffered losses from Nutex Health Inc. (NASDAQ: NUTX) securities between August 8, 2024, and August 15, 2025, are encouraged to contact Faruqi & Faruqi, LLP. The firm is investigating potential claims against the company and has set a deadline of October 21, 2025, for investors to seek the role of lead plaintiff in a federal securities class action lawsuit [3].The lawsuit alleges that Nutex Health Inc. violated federal securities laws by making false and/or misleading statements and/or failing to disclose key information. Specifically, the complaint alleges that Nutex engaged in a coordinated scheme with HaloMD to defraud insurance companies, resulting in unsustainable revenues. Additionally, the company overstated its ability to remediate material weaknesses in its internal controls over financial reporting and improperly calculated stock-based compensation obligations [1][2][3].
Investors who purchased or acquired Nutex securities during the specified period are urged to contact Faruqi & Faruqi partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The firm has a proven track record of recovering hundreds of millions of dollars for investors since its founding in 1995.
References:
[1] https://www.prnewswire.com/news-releases/nutex-health-nutx-securities-suit-alleges-fraud-and-financial-misstatements---hagens-berman-302538433.html
[2] https://www.morningstar.com/news/business-wire/20250825464928/nutx-investors-have-opportunity-to-lead-nutex-health-inc-securities-fraud-lawsuit-with-the-schall-law-firm
[3] https://www.marketscreener.com/news/investor-deadline-approaching-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-nu-ce7c50dede89f726
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet